Your browser doesn't support javascript.
loading
TGFß receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Melisi, Davide; Garcia-Carbonero, Rocio; Macarulla, Teresa; Pezet, Denis; Deplanque, Gael; Fuchs, Martin; Trojan, Jorg; Kozloff, Mark; Simionato, Francesca; Cleverly, Ann; Smith, Claire; Wang, Shuaicheng; Man, Michael; Driscoll, Kyla E; Estrem, Shawn T; Lahn, Michael M F; Benhadji, Karim A; Tabernero, Josep.
Afiliación
  • Melisi D; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, Università degli studi di Verona, Piazzale L.A. Scuro, 10, 37134, Verona, Italy. davide.melisi@univr.it.
  • Garcia-Carbonero R; University Hospital Doce de Octubre, Institute of Health Research Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain.
  • Macarulla T; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, CIBERONC, Barcelona, Spain.
  • Pezet D; Digestive Surgery Service, CHU Clermont-Ferrand, University Clermont Auvergne, Clermont-Ferrand, France.
  • Deplanque G; Medical Oncology, Saint Joseph Hospital, Paris, France.
  • Fuchs M; Hospital Bogenhausen, Municipal Hospital Munich GmbH, Munich, Germany.
  • Trojan J; Goethe University Medical Center, Frankfurt, Germany.
  • Kozloff M; Ingalls Memorial Hospital, Harvey, IL, USA.
  • Simionato F; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, Università degli studi di Verona, Piazzale L.A. Scuro, 10, 37134, Verona, Italy.
  • Cleverly A; Eli Lilly and Company, Erl Wood, UK.
  • Smith C; Eli Lilly and Company, Erl Wood, UK.
  • Wang S; BioStat Solutions, Inc, Frederick, MD, USA.
  • Man M; Eli Lilly and Company, Indianapolis, IN, USA.
  • Driscoll KE; Eli Lilly and Company, Indianapolis, IN, USA.
  • Estrem ST; Eli Lilly and Company, Indianapolis, IN, USA.
  • Lahn MMF; Eli Lilly and Company, Indianapolis, IN, USA.
  • Benhadji KA; Eli Lilly and Company, Indianapolis, IN, USA.
  • Tabernero J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, CIBERONC, Barcelona, Spain.
Cancer Chemother Pharmacol ; 83(5): 975-991, 2019 05.
Article en En | MEDLINE | ID: mdl-30887178
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Factores de Crecimiento Transformadores beta / MicroARNs Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Cancer Chemother Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Factores de Crecimiento Transformadores beta / MicroARNs Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Cancer Chemother Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Alemania